Cargando…
Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial
BACKGROUND: The side effects of chemotherapy-induced nausea and vomiting (CINV) and myelosuppression reduce the cancer patients’ adherence to chemotherapy. Many Chinese patients choose Chinese medicine (CM) during chemotherapy to reduce side effects; however, the evidence is lacking. The efficacy of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385693/ https://www.ncbi.nlm.nih.gov/pubmed/34432206 http://dx.doi.org/10.1007/s11655-021-3448-9 |
_version_ | 1783742139852652544 |
---|---|
author | Zhang, Tong Fei, Yu-tong Xu, Yun Sun, Ling-yun He, Bin Yan, Shao-hua Tang, Mo Yan, Yun-zi Mao, Jun Yang, Yu-fei |
author_facet | Zhang, Tong Fei, Yu-tong Xu, Yun Sun, Ling-yun He, Bin Yan, Shao-hua Tang, Mo Yan, Yun-zi Mao, Jun Yang, Yu-fei |
author_sort | Zhang, Tong |
collection | PubMed |
description | BACKGROUND: The side effects of chemotherapy-induced nausea and vomiting (CINV) and myelosuppression reduce the cancer patients’ adherence to chemotherapy. Many Chinese patients choose Chinese medicine (CM) during chemotherapy to reduce side effects; however, the evidence is lacking. The efficacy of a CM herbal treatment protocol, Jianpi Bushen Sequential Formula (健脾补肾续贯方, JBSF) will be evaluated on chemotherapy completion rate among patients with colon cancer. METHODS: A multi-center double-blind randomized controlled trial (RCT) will be conducted on 400 patients with colon cancer who will receive 8 cycles of adjuvant chemotherapy with oxaliplatin and capecitabine (CAPEOX). Patients will be randomized 1:1 to receive the JBSF or placebo formula. The primary outcome is the overall chemotherapy completion rate. The secondary outcomes include individual chemotherapy completion rate, 4-cycle completion rate of chemotherapy, time to treatment failure, relative dose intensity and treatment toxicity. Follow-up visits will be scheduled before every and after last chemotherapy. DISCUSSION: This study will provide evidence on whether JBSF can improve the chemotherapy completion rate and reduce side effects among patients with colon cancer. (Trial registration: ClinicalTrials.gov, No. NCT03716518) |
format | Online Article Text |
id | pubmed-8385693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-83856932021-08-25 Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial Zhang, Tong Fei, Yu-tong Xu, Yun Sun, Ling-yun He, Bin Yan, Shao-hua Tang, Mo Yan, Yun-zi Mao, Jun Yang, Yu-fei Chin J Integr Med Original Article BACKGROUND: The side effects of chemotherapy-induced nausea and vomiting (CINV) and myelosuppression reduce the cancer patients’ adherence to chemotherapy. Many Chinese patients choose Chinese medicine (CM) during chemotherapy to reduce side effects; however, the evidence is lacking. The efficacy of a CM herbal treatment protocol, Jianpi Bushen Sequential Formula (健脾补肾续贯方, JBSF) will be evaluated on chemotherapy completion rate among patients with colon cancer. METHODS: A multi-center double-blind randomized controlled trial (RCT) will be conducted on 400 patients with colon cancer who will receive 8 cycles of adjuvant chemotherapy with oxaliplatin and capecitabine (CAPEOX). Patients will be randomized 1:1 to receive the JBSF or placebo formula. The primary outcome is the overall chemotherapy completion rate. The secondary outcomes include individual chemotherapy completion rate, 4-cycle completion rate of chemotherapy, time to treatment failure, relative dose intensity and treatment toxicity. Follow-up visits will be scheduled before every and after last chemotherapy. DISCUSSION: This study will provide evidence on whether JBSF can improve the chemotherapy completion rate and reduce side effects among patients with colon cancer. (Trial registration: ClinicalTrials.gov, No. NCT03716518) Springer Singapore 2021-08-25 2021 /pmc/articles/PMC8385693/ /pubmed/34432206 http://dx.doi.org/10.1007/s11655-021-3448-9 Text en © The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Zhang, Tong Fei, Yu-tong Xu, Yun Sun, Ling-yun He, Bin Yan, Shao-hua Tang, Mo Yan, Yun-zi Mao, Jun Yang, Yu-fei Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial |
title | Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial |
title_full | Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial |
title_fullStr | Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial |
title_full_unstemmed | Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial |
title_short | Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer: Study Protocol for a Randomized Controlled Trial |
title_sort | effect of jianpi bushen sequential formula on adjuvant chemotherapy of colon cancer: study protocol for a randomized controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385693/ https://www.ncbi.nlm.nih.gov/pubmed/34432206 http://dx.doi.org/10.1007/s11655-021-3448-9 |
work_keys_str_mv | AT zhangtong effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT feiyutong effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT xuyun effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT sunlingyun effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT hebin effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT yanshaohua effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT tangmo effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT yanyunzi effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT maojun effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial AT yangyufei effectofjianpibushensequentialformulaonadjuvantchemotherapyofcoloncancerstudyprotocolforarandomizedcontrolledtrial |